Latest News and Press Releases

- Primary Endpoint of Safety and Efficacy Met with Clinical Activity and Increased Survival Observed - - 70.3 Weeks Median Overall Survival for Patients Treated with Combination Therapy; Median...

- SLS009 Demonstrated Promising Efficacy in Phase 1 Study with 36.4% Clinical Response (ORR) in r/r Peripheral T-cell Lymphomas (PTCL); ORR in r/r PTCL Patients with Standard of Care is 25.8% - - One...

- Enrollment Completed in 45 mg Safety Cohort; Safety Monitoring Committee Advocated Proceeding to Recommended Phase 2 Dose Level of 60 mg - - Patients in 60 mg Dose Cohort Will be Dosed with 60 mg...

NEW YORK, Dec. 13, 2023 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS’’ or the “Company”), a late-stage clinical biopharmaceutical company focused on the development of...

- Independent Data Monitoring Committee (IDMC) Recommended Continuation of Phase 3 REGAL Trial Without Any Modifications - - IDMC Expressed Satisfaction with Speed of Enrollment and High Study...

NEW YORK, Nov. 29, 2023 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS’’ or the “Company”), a late-stage clinical biopharmaceutical company focused on the development of...

– FDA feedback indicates Company’s CMC plans are in alignment with FDA’s requirements and expectations towards a BLA – – CMC regulatory alignment is critical step in approval pathway for GPS – ...

-Phase 3 REGAL Trial of Galinpepimut-S (GPS) on Track to Complete Enrollment ex-China in November 2023 - - Positive Initial Topline Phase 2a Data of SLS009 Reported with First Complete Response...

Median overall survival for GPS and Keytruda® combination was 18.4 Months compared to 13.8 Months in a Keytruda® single agent study (KEYNOTE-028) and 11-14 Months with standard of care...

NEW YORK, Oct. 31, 2023 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS’’ or the “Company”), a late-stage clinical biopharmaceutical company focused on the development of...